Revalesio Receives FDA Fast Track Designation for RNS60 for the Treatment of Acute Ischemic Stroke
Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to RNS60, its lead investigational therapy, for the treatment of acute ischemic stroke. This designation is intended to accelerate the development and review of RNS60, which could fill […]